top of page
* FDA APPROVES FIRST TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY TO TREAT SOLID TUMORS (FEB 2024)
⮕ PBL-T is a SMART version of TIL (Next-generation TIL)
About Us
MEGENE Therapeutics is a Cell and Gene Therapy company focused on developing innovative programs for "Enhanced Selected Circulating TIL" and "Enhanced CAR-T" products.
Our “RIV-8 platform” effectively combats T-cell exhaustion, providing potential solutions even for terminally exhausted T cells. With our RIV-8 technology, we are at the forefront of addressing T-cell exhaustion in CAR-T/TIL /CPI (Check Point Inhibitors) therapies. Furthermore, our “PBL-T platform,” which selects neoantigen reactive T cells from peripheral blood, is geared toward developing products for treating solid tumors.
We are dedicated to addressing rare, orphan, and high unmet needs in treating solid tumors.
MEDGENE Therapeutics is
A T cell Therapy Company developing Next Gen TIL combining two platform technologies
AUTO-T
Next Gen c-TIL
( Selected + Engineered + Circulating )
PBL-T (C-TIL*)
Neoantigen reactive TIL from peripheral blood -> ACT
*circulating tumor infiltrating lymphocytes
RIV-8
Reprogramming T cells for Exhausting Suppression and Reinvigoration
Our Technologies
Our two foundational technologies are 1) PBL-T – Highly tumor-reactive circulating TIL derived from the peripheral blood that was developed in the Steve Rosenberg lab at NIH and 2) RIV-8 – a genetically modified T-cell that has been shown to prevent and
overcome T-cell exhaustion.
PBL-T
PBL-T is SMART-TIL
-
Selecting Neoantigen-specific CD8+T cells from the peripheral blood
-
No surgery required (Easier sample collection, more addressable tumors)
-
Better cell quality than conventional TIL
- Less Exhausted T cells
- More Stem-like cell stage
RIV-8
RIV-8 is a Breakthrough Gene Reprogramming Technology (GAME CHANGER!!)
-
Genetic Reprogramming Designed to Prevent Exhaustion and Reinvigorate Exhausted T Cells
- Even the terminally exhausted T cells could be reinvigorated by our RIV-8 platform (GAME CHANGER!!)
-
RIV-8 can be applied to a wide array of ACTs (CAR-T, TCR-T, TIL) and CPI
-
RIV-8 has multiple options for delivery tools - Huge potential
- RIV-8 can be delivered using various tools, including AAV, mRNA, nanoparticles, and more.
Our Pipeline
SMART-TIL
RIV-8
CORPORATE OVERVIEW
Leadership Management Team
Contact Us
Adress-USA
9841 Washingtonian Blvd, Suite 200, Gaithersburg, MD 20878, USA
Adress-SOUTH KOREA
105-1-dong Room 203, Start-up Incubation Center, Genetic Engineering Research Institute, Seoul National University, Gwanak-ro 1, Gwanak-gu, Seoul, SOUTH KOREA
bottom of page